The Relation Between Epicardial Fat Tissue Thickness and TSH Receptor Antibody in Hyperthyroidism

Abstract

Background Although hyperthyroidism may be associated with atherosclerosis, its pathogenesis is not well known. TSH receptor antibody (TRAb) has been shown to be responsible for increased orbital fat tissue in Graves ophthalmopathy. Epicardial fat tissue thickness (EFT) has been found to be increased in case of overt hyperthyroidism. In our study, we aimed to investigate if TRAb is associated with the increased EFT in newly diagnosed hyperthyroidism.

Methods Twenty six TRAb positive (group 1) and 26 TRAb negative (group 2) newly diagnosed patients with hyperthyroidism, and 26 healthy control subjects (group 3) were enrolled. EFT was measured by the same cardiologist using an echocardiography device. Serum TRAb levels were measured by the radio-receptor assay and levels above 1.75 IU/L were considered as positive.

Results There was no difference among groups in terms of age, gender and body mass index. Although there was no significant difference between group 1 and 2, both group 1 (0.38±0.15 cm) and group 2 (0.4±0.17 cm) had significantly higher EFT levels when compared to group 3 (0.25±0.06 cm) (p=0.004 and p=0.001, respectively). However we did not find any correlation between TRAb and EFT levels.

Conclusion The results of our study suggested that EFT was increased in hyperthyroidism and this increasing was not dependent of TRAb level. EFT elevation might be depending directly to the cardiovascular effects of hyperthyroidism.

Key words

hyperthyroidism - TSH receptor antibody - epicardial fat tissue thickness

• References

• 1 Polikar R, Burger A, Scherrer U. et al. The thyroid and the heart. Circulation 1993; 87: 1435-1441
• 2 Kahaly GJ, Dilmann WH. Thyroid hormone action in the heart. Endocrine Reviews 2005; 26: 704-728
• 3 Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-509
• 4 Harun S. The correlation between free thyroxine levels and left ventricular mass in Graves' disease. Acta Med Indones 2006; 38: 193-195
• 5 Bilir C, Gökosmanoglu F, Caliskan M. et al. Regression of the carotid intima media thickness by propylthiouracil therapy in Graves' hyperthyroidism. Am J Med Sci 2012; 343: 273-276
• 6 Völzke H, Robinson DM, Schminke U. et al Thyroid function and carotid wall thickness. J Clin Endocrinol Metab 2004; 89: 2145-2149
• 7 Binnetoğlu E, Asik M, Altun B. et al. Evaluation of epicardial fat tissue thickness in patients with hyperthyroidism. Wien Klin Wochenschr 2014; 126: 485-490
• 8 Şengül C, Özveren O. Epicardial adipose tissue: A review of physiology, pathophysiology, and clinical applications. Anadolu Kardiyol Derg 2013; 13: 261-265
• 9 Menconi F, Marcocci C, Marinò M. Diagnosis and classification of Graves' disease. Autoimmun Rev 2014; 13: 398-402
• 10 Bahn RS. Graves’ ophthalmopathy. N Engl J Med 2010; Feb 25 362: 726-738
• 11 Gerding MN, van der Meer JW, Broenink M. et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2000; 52: 267-271
• 12 Mallika P, Tan A, Aziz S. et al. Thyroid Associated Ophthalmopathy – A Review. Malays Fam Physician 2009; 4: 8-14
• 13 Khoo TK, Bahn RS. Pathogenesis of Graves’ ophthalmopathy: The role of autoantibodies. Thyroid 2007; 17: 1013101-1013108
• 14 Khoo DH, Eng PH, Ho SC. et al. Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: Prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 2000; 10: 1093-1100
• 15 Khoo DH, Ho SC, Seah LL. et al. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves’ disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 1999; 9: 1175-1180
• 16 Kumar S, Nadeem S, Stan MN. et al. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves’ ophthalmopathy. J Mol Endocrinol 2011; 46: 155-163
• 17 Mazurek T, Zhang L, Zalewski A. et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003; 108: 2460-2466
• 18 Bos D, Shahzad R, van Walsum T. et al. Epicardial fat volume is related to atherosclerotic calcification in multiple vessel beds. Eur Heart J Cardiovasc Imaging 2015; 16: 1264-1269
• 19 Nabati M, Saffar N, Yazdani J. et al. Relationship between epicardial fat measured by echocardiography and coronary atherosclerosis: A single-blind historical cohort study. Echocardiography 2013; 30: 505-511
• 20 Baragetti A, Pisano G, Bertelli C. et al. Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. Nutr Metab Cardiovasc Dis 2016; 26: 141-153
• 21 Şahin M, Gökçay Canpolat A, Çorapçioğlu D. et al. Association between Circulating Irisin Levels and Epicardial Fat in Patients with Treatment-Naïve Overt Hyperthyroidism. Biomarkers 2018; 4: 1-18
• 22 Collet TH, Gussekloo J, Bauer DC. et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172: 799-809
• 23 Balta S, Demirkol S, Kurt Ö. et al. Epicardial adipose tissue measurement: inexpensive, easy accessible and rapid practical method. Anadolu Kardiyol Derg 2013; 13: 611